featured
Sunitinib Schedule Modification Improves Safety in Patients With Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Sunitinib Dosing Schedule in Metastatic Renal Cell Carcinoma
- Alternating Sunitinib and Everolimus Is Not Efficacious As First-Line Therapy for aRCC
- Standard and Adapted Sunitinib Regimen Equivalent in Elderly Patients With Metastatic RCC
- VIDEO: Alternate Dose Scheduling Strategies in RCC
- Alternate Sunitinib Schedules for Metastatic RCC
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sunitinib Administered on 2/1 Schedule in Patients With Metastatic Renal Cell Carcinoma: The RAINBOW Analysis
Ann. Oncol 2015 Jul 27;[EPub Ahead of Print], S Bracarda, R Iacovelli, L Boni, M Rizzo, L Derosa, M Rossi, L Galli, G Procopio, M Sisani, F Longo, M Santoni, F Morelli, G Di Lorenzo, A Altavilla, C Porta, A Camerini, B EscudierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.